Compass Pathways surprised and disappointed the market with its Phase IIb clinical results. Despite the immediate overall selloff on the news, the outlook for many psychedelic stocks is now BETTER.
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
CYB003 is demonstrating superior treatment properties vs. an oral dosage of psilocybin.
MINDCURE Positioned For Strong Run In 2022 – CEO Q&A
MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
Novamind Reports FY2021 Financial Results and Operating Highlights
Novamind reports its full year results for fiscal 2021, including industry-leading revenue of CAD$6 million.
MINDCURE’s Update Hints At Big Things To Come
As MINDCURE's iSTRYM digital therapeutics platform rapidly gathers momentum, the company looks poised to join the emerging rally in the sector.
Cybin Granted DEA Schedule I Manufacturing License
Cybin announces receiving its DEA Schedule I Manufacting License, necessary to work with Schedule I controlled substances in the U.S.
MINDCURE Provides Update on Studies and Clinical Trials
Mind Cure Health Inc., is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology.
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol "DRUG"
Bright Minds Biosciences announces it has uplisted to the NASDAQ, trading under the symbol "DRUG".
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Compass Pathways lifted the whole sector in 2020. With CMPS again rising, is history about to repeat?
Red Light Holland Appoints New Chief Financial Officer
Red Light Holland appoints a new Chief Financial Officer, David Ascott.
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform
MINDCURE announces an LOI with Awaken Life Sciences for the deployment of MINDCURE's iSTRYM digital therapeutics platform in Awaken's addiction treatment clinics.
